Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05534347
Recruiting Observational

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

NCT05534347 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2023-03-13
Last updated
2025-09-12

Condition(s) studied

Juvenile Idiopathic Arthritis (JIA)

Investigational drug(s) / intervention(s)

Blood sample →Joint puncture

Blood sample: Addtional tube of blood needed for follow up of patients

Joint puncture: Joint puncture if needed according to routine care of the patients

Study summary

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Greater than or equal to 16 years-old * Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital * No-opposition to the research * Patient with health insurance * Mastery of the French language Exclusion Criteria: * Patient under curatorship or guardianship * Patient receiving french state medical aid

Primary outcome measure(s)

  • Dosage of angiogenic markers — 5 years
    Dosage of angiogenic markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
  • Dosage of angiogenic markers — 5 years
    Dosage of angiogenic markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
  • Dosage of inflammatory markers by ELISA method — 5 years
    Dosage of inflammatory markers by ELISA method in serum. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.
  • Dosage of inflammatory markers by ELISA method — 5 years
    Dosage of inflammatory markers by ELISA method in synovial fluid if available. Determine if angiogenic and inflammatory biomarkers are predictive of a more severe disease as reflected by structural joint damage and treatments received. Activity measured with questionnaires, and treatments received. Structural damage determined by x-rays during follow up.

Trial sites (1)

FacilityCityRegionStatus
Rheumatology Department, Cochin Hospital Paris IDF Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer Recruiting
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study Recruiting
Primitive Immunodeficiency, Intrauterine Devices and Menstrual Hygiene Products Recruiting
Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting

Other trials for the same condition

OLE Study With Filgotinib in JIA Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05534347 on ClinicalTrials.gov ↗ ← All trials in France